Purpose Primary intraocular lymphoma (PIOL) is a rare malignancy with an aggressive clinical course. It is usually considered as a subset of primary central nervous system lymphoma. Differential diagnosis should include infectious and non-infectious aetiologies, particularly the common masqueraders sarcoidosis, tuberculosis, viral retinitis and syphilis. Patient The article presents a case of bilateral vitreoretinal lymphoma manifesting as uveitis and vitritis resistant to corticosteroid therapy. The final diagnosis was based on a retinal biopsy. Results The patient was successfully treated with systemic and local therapy. Long-term complete remission (CR) was reached. The relapse of diffuse large B-cell lymphoma was revealed in the frontal left lobe after 48 months of CR duration. Conclusion The diagnosis of PIOL is always very difficult. Cooperation of pathologists, ophthalmologists and hematologists is required for a quick and accurate diagnosis. Local and systemic treatment is needed to achieve CR, but the relapse rate remains very high.
Introduction
Primary intraocular lymphoma (PIOL) is a rare malignancy with an aggressive clinical course. It is usually considered as a subset of primary central nervous system lymphoma (PCNSL) [1] . The vast majority of PIOL cases are diffuse large B-cell lymphoma (DLBCL). Less common histologies include T-cell PCNSL, Burkitt, lymphoblastic and marginal zone lymphomas [1] . Nearly 20 % of PCNSL cases present with intraocular involvement with cellular infiltrates in the vitreous and retina. Diagnosis is always a challenge, as the disease can mimic steroid-resistant ocular inflammation [2] . Here we present a case of retinochoroidal primary DLBCL of both eyes, successfully diagnosed by a retinal biopsy and treated with systemic and intravitreal chemotherapy.
Case Presentation
A 59-year-old, European woman with a 15-year history of pulmonary tuberculosis initially had presented a decrease of visual acuity (VA) in the left eye, which had slowly progressed since July 2008. The patient was admitted to the Department of Ophthalmology in Wroclaw Medical University in December 2008 with a significant decrease of vision in this eye. Her VA was 1.0 cc ? 1.25 Dsph in the right eye and counting fingers from 10 cm in the left eye. Anterior segment was within normal limits in both eyes. The posterior segment was normal in the right eye, and vitritis in the left eye was noticed with a poor view of the (Fig. 4) . Stereotactic biopsy of the tumour confirmed DLBCL. The patient underwent chemotherapy consisting of high doses of Ara-C (6.4 g i.v.), MTX (6.4 i.v.) and dexamethasone, with no clinical or radiological response. Radiation therapy of CNS (50 Gy/wl) brought a temporary improvement, but the patient died 2 months after the DLBCL's relapse was diagnosed.
Discussion
Diagnosis of PIOL can be challenging. It requires a high degree of clinical suspicion. Differential diagnosis should include infectious and non-infectious aetiologies, particularly the common masqueraders such as sarcoidosis, tuberculosis, viral retinitis and syphilis [2] . This rare disease should be suspected in all patients with uveitis resistant to corticosteroid therapy and in elderly patients with a recent onset of vitritis [3] . Patients typically complain of decreased vision, painless blurred vision and floaters, most likely secondary to the chronic vitritis and subretinal lesions. Some patients are asymptomatic and are diagnosed only when examined following diagnosis of PCNSL. PIOL is a subset of PCNSL and is usually an aggressive DLBCL. Central nervous system involvement will occur in 50-80 % of patients of PIOL after the onset of ocular symptoms. Conversely, 15-25 % of patients with PCNSL have ocular involvement. The most common ocular manifestations are posterior uveitis or vitritis. Characteristically, PIOL tends to be bilateral. The major risk factors for PIOL/PCNSL are immunodeficiency and immunosuppression [4] . Definitive diagnosis still requires harvesting of a sufficient amount of good quality tissue that is kept fresh for histopathological analysis [4] . The optimal treatment of PIOL includes high dose of systemic chemotherapy (MTX/Ara-C) with common complete remission, although relapse is frequent. Intravitreal MTX can be used successfully in some patients but disease relapse is common when therapy is discontinued. Orbital radiation can lead to remission, but there are many adverse events, such as dry eye, optic neuropathy and retinopathy, and it does not prolong survival. Rituximab given both systematically and intravitreally was used based on its efficacy, with a good initial response, but subsequent relapse required intravitreal MTX and radiation [5, 6] . PIOL is associated with a poor prognosis, with patients dying of CNS disease; therefore appropriate diagnosis is crucial for the treatment. In our patient the combination therapy-intravenous, intravitreal and intrathecal-led to long-term complete remission which continued for 49 months. Relapse was confirmed in CNS with no infiltration within the orbits, but resistance to chemotherapy and radiotherapy was observed. According to the other data, the relapse of PIOL is frequent in the brain, spinal cord and the meningeal localization, and despite high doses of chemotherapy the course is often fatal. Follow-up periods range from 12 to 35 months, with mortality rates up to 81 % [7] . The optimal approach includes either systemic or intraocular chemotherapy, which delays the relapse and may influence the overall survival.
Conclusion
The diagnosis of PIOL is highly difficult. Cooperation of pathologists, ophthalmologists and hematologists is required for a quick and accurate diagnosis. Local and systemic treatment is needed to achieve complete remission, but the relapse rate remains very high.
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